About Heiner Dreismann
Heiner Dreismann is a director at Inflammatix. He joined its board in July 2023. Inflammatix develops rapid tests that read immune responses to help doctors diagnose acute infections and sepsis. He has more than 35 years of life sciences and health care experience. His career included early use of a common laboratory method called polymerase chain reaction, or PCR.
He earned graduate degrees in biology and microbiology at Westfaelische Wilhelms University. After a postdoctoral fellowship near Paris, he joined Roehm and Haas. He joined F. Hoffmann La Roche in 1985 and later led its European PCR business and strategic planning for PCR diagnostics. From 2000 through 2006, he was president and CEO of Roche Molecular Systems. He was CEO of Vectrant Technologies from 2006 through 2009 and became interim CEO of GeneNews in 2008. Singulex appointed him to its board in 2007. He later served there as lead independent director. In 2012, he also served on the Myriad Genetics, Med BioGene and GeneNews boards.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Heiner Dreismann in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Heiner Dreismann works with at each company, as listed on that company's latest Form D.



